Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service vitreoretinal surgery cases in Alabama: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (216 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 24 | 1,713 | 45% |
| 2020 | 21 | 1,692 | 49% |
| 2021 | 23 | 1,358 |
Pars plana vitrectomy and retinal detachment repair. Professional codes (what the surgeon bills): CPT 67036, 67040, 67041, 67042, 67108, 67113.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 77% of the cases CMS names in Alabama; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Cataract & MIGS | 102 | 35,688−2.7%/yr | −2.7%/yr | 79.51.4× | 83% | 29,500 in 2030−3.1%/yr |
Vitreoretinal surgery in every state, and its device makers · Every procedure market in Alabama · Every state · Compare with Texas
| 2024 |
| 1,215 |
| 64% |
| 2025 est. | ≈ 1,210 | – |
| 2026 est. | ≈ 1,190 | – |
| 54% |
| 2022 | 21 | 1,268 | 58% |
| 2023 | 24 | 1,294 | 62% |
| 2024 | 18 | 1,215 | 64% |
| 2025 from claims | – | 1,205 1,106–1,275 | 65% |
| 2026 forecast | – | 1,194 1,051–1,378 | 66% |
| 2027 forecast | – | 1,188 1,016–1,416 | 67% |
| 2028 forecast | – | 1,182 986–1,447 | 68% |
| 2029 forecast | – | 1,175 960–1,474 | 68% |
| 2030 forecast | – | 1,167 935–1,496 | 69% |
In 2025, 55% hospital outpatient, 44% surgery center, 1% office. The share outside the hospital has moved +22 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| −2.9%/yr |
| 2.9 |
| 87% |
| 6,520 in 2030+0.3%/yr |
| Tennessee | 36 | 2,272−2.5%/yr | −2.5%/yr | 3.3 | 77% | 2,320 in 2030+0.3%/yr |
| North Carolina | 33 | 2,261−4%/yr | −4%/yr | 2.3 | 36% | 2,170 in 2030−0.7%/yr |
| Maryland | 30 | 2,121−7.2%/yr | −7.2%/yr | 2.4 | 26% | 2,290 in 2030+1.3%/yr |
| Virginia | 28 | 1,985−3.8%/yr | −3.8%/yr | 1.9 | 77% | 2,080 in 2030+0.8%/yr |
| South Carolina | 22 | 1,644−1.1%/yr | −1.1%/yr | 2.4 | 69% | 1,760 in 2030+1.1%/yr |
| Georgia | 19 | 1,497−3.1%/yr | −3.1%/yr | 1.8 | 88% | 1,580 in 2030+0.9%/yr |
| Louisiana | 14 | 1,034−4.5%/yr | −4.5%/yr | 2.6 | 72% | 980 in 2030−1%/yr |
| Oklahoma | 14 | 1,019−4.8%/yr | −4.8%/yr | 2.1 | 77% | 1,020 in 2030+0.1%/yr |
| Mississippi | 11 | 1,000−1.3%/yr | −1.3%/yr | 2.7 | 72% | 1,010 in 2030+0.2%/yr |
| Kentucky | 16 | 944−6.8%/yr | −6.8%/yr | 2.1 | 85% | 910 in 2030−0.5%/yr |
| Arkansas | 10 | 687−6.8%/yr | −6.8%/yr | 1.8 | 0% | 580 in 2030−2.7%/yr |
| West Virginia | 4 | 208−16%/yr | −16%/yr | 1.0 | 73% | 310 in 2030+6.8%/yr |
| District of Columbia | 3 | 175−2.1%/yr | −2.1%/yr | 2.8 | 51% | 260 in 2030+6.9%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Alcon leads with 50% of company spending on these surgeons in 2025, −23 pts on 2024.
In 2025, 11 companies reported engagement with Alabama’s surgeons worth $146K in consulting, speaking, meals and travel tied to these products, about $8,115 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 0 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.